Loading
VO
Voluntis Stock: price and insider trades · France
Voluntis: what insiders have been doing
This page follows insider dealings at Voluntis as filed with AMF, a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Voluntis. The previous disclosure was published on 11 December 2021.
The full history, which starts in 2021, counts no purchases against 5 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.
Insider Decl.
15
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€26M
5 ops. · all time
Financial data
· cache
Last declaration on 11 December 2021
Declarations15 total
83,338 shares@ €8.7050.0% of flowExercice promesse d'achat et signature contrat de cession d'actions sousHors plateforme de négociationISIN FR00041839602021DD765099
681,267 shares0ActionHors plateforme de négociationISIN FR00041839602021DD765106
213,400 shares@ €8.7050.0% of flowExercice promesse d'achat et signature contrat de cession d'actions sousHors plateforme de négociationISIN FR00041839602021DD765108
87,348 shares@ €8.7050.0% of flowExercice promesse d'achat et signature d'un contrat de cession d'actions sousHors plateforme de négociationISIN FR00041839602021DD765183
681,267 shares@ €8.70100.0% of flowActionHors plateforme de négociationISIN FR00041839602021DD769504
87,348 shares@ €8.7050.0% of flowActionHors plateforme de négociationISIN FR00041839602021DD769399
213,400 shares@ €8.7050.0% of flowActionHors plateforme de négociationISIN FR00041839602021DD769375
83,338 shares@ €8.7050.0% of flowActionHors plateforme de négociationISIN FR00041839602021DD769371
1,890,974 shares@ €8.7050.0% of flowActionHors plateforme de négociationISIN FR00041839602021DD769355
1,890,974 shares@ €8.7050.0% of flowExercice promesse d'achat et signature d'un contrat cession d'actions sousHors plateforme de négociationISIN FR00041839602021DD765058
213,400 shares0ActionHors plateforme de négociationISIN FR00041839602021DD761184
87,348 shares0ActionHors plateforme de négociationISIN FR00041839602021DD761183
83,338 shares0ActionHors plateforme de négociationISIN FR00041839602021DD761182
681,267 shares0ActionHors plateforme de négociationISIN FR00041839602021DD761166
1,890,974 shares0ActionHors plateforme de négociationISIN FR00041839602021DD760918
15 of 15 declarations
About Voluntis
Voluntis is a French company specialized in digital therapeutics, i.e. clinically validated software designed to support the management of patients living with chronic diseases. Over time, the group built its expertise around software platforms that combine patient data, therapeutic algorithms and clinical protocols, with an early focus on oncology and diabetes. The company was listed on Euronext Paris in May 2018 under ISIN code FR0004183960, before becoming a strategic acquisition target for U.S.-based Aptar in 2021. Aptar subsequently completed the purchase of a majority stake, representing about 64.6% of Voluntis’ share capital, and then launched a simplified tender offer followed by a squeeze-out. This marked a major milestone in Voluntis’ corporate history and confirmed the industrial value of its technology.
Voluntis’ core business is the development of digital therapeutic solutions that help personalize patient care, improve treatment adherence and facilitate interaction between patients, healthcare professionals and pharmaceutical companies. Its products and services are primarily aimed at pharmaceutical groups, digital health players and, more broadly, healthcare ecosystems seeking validated digital monitoring tools. The company has notably worked on support programs in oncology, where optimized care pathways and remote monitoring are especially important.
Read moreShow less
From a commercial standpoint, Voluntis positioned itself as one of the European pioneers in digital health, with the ability to deploy its solutions across multiple international markets. Historically, its footprint was organized between France and the United States, particularly around Paris and Cambridge, Massachusetts, allowing it to combine product innovation with access to the North American market. The company also formed partnerships with healthcare groups and medical interoperability specialists to strengthen integration of its solutions into care systems.
A notable feature of Voluntis is that it entered a still-emerging niche at a very early stage: clinically validated digital therapeutics. Its trajectory reflects both the rise of digital medicine and the consolidation of the sector around players able to offer solutions that are regulatory-grade, technology-driven and focused on measurable clinical outcomes.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
